John V Heymach

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters
    Yong He
    Department of Thoracic Surgery, Daping Hospital, Third Military Medical University, Chongqing, China
    PLoS ONE 7:e31087. 2012
  2. doi request reprint The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
    Petros Nikolinakos
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Thorac Oncol 3:S131-4. 2008
  3. pmc Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer
    John V Heymach
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer Prev Res (Phila) 4:1590-8. 2011
  4. ncbi request reprint Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer
    John V Heymach
    Department of Thoracic Head and Neck Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 12:4441s-4445s. 2006
  5. pmc An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
    Lauren Averett Byers
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 19:279-90. 2013
  6. pmc Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
    Pierre Saintigny
    Department of 1Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center 5The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA
    Mol Cancer Ther 11:2021-32. 2012
  7. pmc Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer
    Emer O Hanrahan
    University of Texas M D, Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:193-201. 2010
  8. pmc Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy
    Vikas Bhardwaj
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 119:1768-75. 2013
  9. pmc Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
    Yuji Piao
    Brain Tumor Center, Department of Neuro Oncology, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Neuro Oncol 14:1379-92. 2012
  10. doi request reprint Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 13:827-37. 2012

Collaborators

Detail Information

Publications64

  1. pmc Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters
    Yong He
    Department of Thoracic Surgery, Daping Hospital, Third Military Medical University, Chongqing, China
    PLoS ONE 7:e31087. 2012
    ..This study aimed to determine protein signatures in primary lung cancer tissues...
  2. doi request reprint The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
    Petros Nikolinakos
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Thorac Oncol 3:S131-4. 2008
    ..These trials will determine whether cediranib will join the growing armamentarium of therapeutic options for thoracic malignancies and broaden the number of patients with NSCLC who could potentially benefit from antiangiogenic therapy...
  3. pmc Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer
    John V Heymach
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer Prev Res (Phila) 4:1590-8. 2011
    ..These results suggest that a LF diet without flaxseed may reduce levels of specific inflammatory CAFs and suggests that the NF-κB pathway may be a mediator of these changes...
  4. ncbi request reprint Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer
    John V Heymach
    Department of Thoracic Head and Neck Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 12:4441s-4445s. 2006
    ....
  5. pmc An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
    Lauren Averett Byers
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 19:279-90. 2013
    ....
  6. pmc Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
    Pierre Saintigny
    Department of 1Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center 5The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA
    Mol Cancer Ther 11:2021-32. 2012
    ..EphA4 gene expression is associated with an improved outcome in patients with resected lung adenocarcinoma, possibly by affecting cancer cell migration and invasion...
  7. pmc Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer
    Emer O Hanrahan
    University of Texas M D, Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:193-201. 2010
    ..It is unknown whether chemotherapy or VEGFR inhibitor/chemotherapy combinations induce changes in these or other cytokines and angiogenic factors (CAFs) and whether such changes could be markers of benefit...
  8. pmc Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy
    Vikas Bhardwaj
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 119:1768-75. 2013
    ..This article summarizes key findings regarding crosstalk between radiotherapy and c-Met and discusses studies performed to date in which c-Met inhibition was used as a strategy to increase cellular radiosensitivity...
  9. pmc Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
    Yuji Piao
    Brain Tumor Center, Department of Neuro Oncology, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Neuro Oncol 14:1379-92. 2012
    ..Collectively, our results demonstrate a more prolonged decrease in tumor vascularity with bevacizumab than with sunitinib, associated with a delay in the development of hypoxia and sustained reduction of infiltrated myeloid cells...
  10. doi request reprint Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 13:827-37. 2012
    ..We aimed to assess the prognostic and predictive associations of pretreatment plasma concentrations of cytokine and angiogenic factors (CAFs) with data from a phase 2 and a phase 3 trial of pazopanib treatment...
  11. doi request reprint A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid
    Peter E Zage
    Division of Pediatrics, Children s Cancer Hospital, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:2465-75. 2010
    ..The authors hypothesized that vandetanib combined with 13-cis-retinoic acid (CRA), a differentiating agent used in most current neuroblastoma treatment regimens, would be effective against neuroblastoma tumor models...
  12. pmc CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma
    Pierre Saintigny
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 73:571-82. 2013
    ..Expression of CXCL5 was regulated by promoter methylation. The CXCR2 axis may be an important target in smoking-related lung adenocarcinoma...
  13. doi request reprint Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer
    Emer O Hanrahan
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 15:3600-9. 2009
    ..In study 7, vandetanib monotherapy was inferior to carboplatin-paclitaxel. We performed an exploratory retrospective analysis of the relationship between baseline circulating VEGF concentrations and PFS...
  14. pmc Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1
    Lauren Averett Byers
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Discov 2:798-811. 2012
    ..On the basis of these results, clinical studies evaluating PARP and EZH2 inhibition, together with chemotherapy or other agents, warrant further investigation...
  15. pmc DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy
    Benjamin J Moeller
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:2035-43. 2011
    ..We examined whether differential expression of double-strand DNA break (DSB) repair proteins in HNSCC, the chief mediators of DNA repair following irradiation, predict for treatment outcomes...
  16. doi request reprint Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib
    Petros G Nikolinakos
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 70:2171-9. 2010
    ..These data suggest that CAF profiling may be useful for identifying patients likely to benefit from pazopanib, and merit further investigation in clinical trials...
  17. pmc Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer
    Lauren Averett Byers
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:1755-63. 2010
    ..In conclusion, serum CAF profiling, particularly in HPV-negative patients, may be useful for identifying those at highest risk for recurrence...
  18. ncbi request reprint Angiogenesis inhibitors for lung cancer: clinical developments and future directions
    George Blumenschein
    Department of Thoracic Head and Neck Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Thorac Oncol 1:744-8. 2006
  19. pmc Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
    Tina Cascone
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 121:1313-28. 2011
    ..Understanding stromal signaling may be critical for developing biomarkers for angiogenesis inhibitors and improving combination regimens...
  20. pmc Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Lancet Oncol 11:619-26. 2010
    ..These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC)...
  21. ncbi request reprint Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer
    Emer O Hanrahan
    Departments of Thoracic Head and Neck Medical Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:s4617-22. 2007
    ....
  22. ncbi request reprint Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer
    Lauren A Byers
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Lung Cancer 8:S79-85. 2007
    ..Phase III clinical trials are currently in progress to determine whether dual VEGF/EGFR inhibition, alone or in combination with chemotherapy, should become a standard therapeutic option for patients with NSCLC...
  23. ncbi request reprint Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:281-8. 2007
    ..05) and led to a decrease in cell-free DNA levels (P < 0.05). Our results suggest that metronomic taxane chemotherapy with dual EGFR and VEGFR inhibition is highly efficacious and should be considered for future clinical trials...
  24. pmc Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
    Xiao Feng Le
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cell Cycle 7:3747-58. 2008
    ..Similar mechanisms may contribute to the clinical anti-tumor activity of trastuzumab in combination with inhibitors of VEGF signaling pathway in women with breast cancers which overexpress HER2...
  25. doi request reprint Lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 359:1367-80. 2008
  26. pmc Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer
    Lauren Averett Byers
    Division of Cancer Medicine and Department of Thoracic Head and Neck Medical Oncology, Unit 432, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Clin Cancer Res 15:6852-61. 2009
    ..Activation of STAT3 by cellular Src (c-Src) promotes tumor progression. We hypothesized that c-Src inhibition could activate STAT3 by inducing a homeostatic feedback loop, contributing to c-Src inhibitor resistance...
  27. pmc Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis
    José Luis López Guerra
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:e61-7. 2012
    ..We investigated prognostic factors associated with survival in patients with non-small cell lung cancer (NSCLC) and oligometastatic disease at diagnosis, particularly the influence of local treatment to the primary site on prognosis...
  28. pmc Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy
    Fei Yang
    Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 71:5512-21. 2011
    ....
  29. pmc Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4872-81. 2011
    ..We investigated potential blood-based markers associated with radiographic changes to aflibercept, which binds VEGF and placental growth factor (PlGF) in patients with recurrent glioblastoma...
  30. pmc Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells
    Xiaoying Liu
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biochem Pharmacol 83:1456-64. 2012
    ..Our results indicate that NSC-743380 is a potent anticancer agent for lung cancer and that its apoptotic effects in lung cancer cells are mediated by induction of ROS through STAT3 inhibition...
  31. pmc Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
    James W Welsh
    Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 31:895-902. 2013
    ..Additional end points were radiologic response and safety...
  32. pmc C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression
    Vikas Bhardwaj
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 7:1211-7. 2012
    ..We hypothesized that inhibiting c-Met would increase the sensitivity of NSCLC cells to radiation, enhancing the therapeutic ratio, which may potentially translate into improved local control...
  33. pmc Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook
    Joaquín Mateo
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Diagn Ther 16:151-61. 2012
    ..These candidate markers should be considered in the development of future combination or sequential therapies...
  34. ncbi request reprint The BATTLE trial: personalizing therapy for lung cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Discov 1:44-53. 2011
    ..BATTLE establishes the feasibility of a new paradigm for a personalized approach to lung cancer clinical trials...
  35. pmc Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    Scott Kopetz
    University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
    J Clin Oncol 28:453-9. 2010
    ....
  36. ncbi request reprint Molecular targets for cancer chemoprevention
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Drug Discov 8:213-25. 2009
    ..Nevertheless, the broad translation of chemoprevention to the clinic is not yet a reality. Continuing research of molecular targets promises to expand the reach of chemoprevention and to personalize it as well...
  37. ncbi request reprint The convergent development of molecular-targeted drugs for cancer treatment and prevention
    Scott M Lippman
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:4035-41. 2007
    ..These several advances are creating a convergence of cancer therapy with cancer prevention that promises to streamline the development of targeted drugs and improve the control of major cancers...
  38. pmc Circulating biomarkers in advanced renal cell carcinoma: clinical applications
    Maria Hernandez-Yanez
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Curr Oncol Rep 14:221-9. 2012
    ..This review summarizes recent developments in identifying circulating biomarkers of targeted therapies for metastatic RCC, including soluble proteins and circulating cells...
  39. pmc Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer
    Shervin M Shirvani
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 82:e91-7. 2012
    ....
  40. ncbi request reprint Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Department of Thoracic Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Expert Opin Investig Drugs 16:239-49. 2007
    ..Clinical development is also ongoing in other tumor types and encouraging evidence of antitumor activity has been reported in patients with metastatic hereditary medullary thyroid cancer...
  41. ncbi request reprint Vascular endothelial growth factor (VEGF) pathway
    Monique Nilsson
    Department of Cancer Biology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Thorac Oncol 1:768-70. 2006
  42. pmc Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
    Robert L Coleman
    Department of Gynecologic Oncology and Reproductive Medicine, M D Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 12:1109-17. 2011
    ..We assessed the safety, tolerance, pharmacokinetics, relevant circulating and image-derived biomarkers, and clinical activity of combination aflibercept and docetaxel in this population...
  43. doi request reprint Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma
    Amado J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030 4009, USA
    Cancer 115:2346-54. 2009
    ..Further preclinical and translational validation studies are still needed to determine their practical utility in the clinical setting...
  44. ncbi request reprint Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research
    Ashraful Hoque
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Res 67:8989-93. 2007
    ....
  45. pmc miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1
    Jonathon D Roybal
    University of Texas MD Anderson Cancer Center, Box 432, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Mol Cancer Res 9:25-35. 2011
    ..Flt1 knockdown decreased the growth and metastasis of tumor cells in syngeneic mice. We conclude that miR-200 suppresses lung tumorigenesis by targeting Flt1...
  46. ncbi request reprint Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
    Darren W Davis
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:678-89. 2005
    ....
  47. pmc Blasted cell line names
    Jing Wang
    Department of Bioinformatics and Computational Biology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Inform 9:251-5. 2010
    ..Most of the variations appeared to involve punctuation, white space, or their absence, at the juncture between alphabetic and numeric portions of the cell line name...
  48. ncbi request reprint Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells
    Tina Cascone
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    J Cell Physiol 216:698-707. 2008
    ....
  49. ncbi request reprint Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity
    Paul Beaudry
    Children s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:3514-22. 2005
    ..We hypothesized that antiangiogenic agents may have differential effects on CEPs and mature CECs and that these changes may serve as a marker of biological activity...
  50. ncbi request reprint Emerging antiangiogenic agents in lung cancer
    David Lee
    CIG Media Group, LP, Dallas, TX, USA
    Clin Lung Cancer 7:304-8. 2006
    ..Data from phase I/II trials have indicated the clinical feasibility of these agents, which are currently being investigated in phase II/III trials...
  51. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  52. pmc Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Clin Invest 116:2695-706. 2006
    ....
  53. ncbi request reprint Farnesyl transferase inhibitors for patients with lung cancer
    Bruce E Johnson
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:4254s-4257s. 2004
    ..R115777 and L-778,123 were well tolerated in these studies but showed no significant activity as single-agent therapy in relapsed SCLC or untreated NSLC...
  54. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  55. doi request reprint Second-line treatment of advanced non-small cell lung cancer
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 3:430-40. 2008
    ..Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents...
  56. ncbi request reprint Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer
    John V Heymach
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:4270-7. 2007
    ..The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC)...
  57. ncbi request reprint PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
    ..These preclinical evaluations support further clinical development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members...
  58. doi request reprint Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  59. ncbi request reprint Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib
    Sendia Kim
    Department of Surgery, Children s Hospital Boston Harvard Medical School, Boston, Massachusetts 02115, USA
    J Surg Res 149:115-9. 2008
    ..To determine the effects of sunitinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist, on intra-abdominal adhesions...
  60. ncbi request reprint Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve
    Ilhan Celik
    Institute of Theoretical Surgery, University Hospital Marburg, Philipps University, Baldingerstrasse, Marburg, Germany
    Cancer Res 65:11044-50. 2005
    ..When these results are taken together with two previous reports of angiogenesis inhibitors with a U-shaped dose-response, they suggest that other regulators of endothelial growth may display a similar pattern...
  61. ncbi request reprint Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells
    Dhara N Amin
    Vascular Biology Program, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Microvasc Res 76:15-22. 2008
    ..Our data provide a molecular rationale for combination therapies targeting both EGF and VEGF signaling on the tumor vasculature...
  62. ncbi request reprint Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
    Clin Cancer Res 13:s4583-8. 2007
    ....
  63. ncbi request reprint Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor
    Anat Norden-Zfoni
    Children s Hospital Boston, Boston, Massachusetts, USA
    Clin Cancer Res 13:2643-50. 2007
    ..In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors...
  64. ncbi request reprint Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
    John V Heymach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 10:5732-40. 2004
    ..This Phase II study was conducted to investigate the safety and efficacy of SU5416 for patients with soft tissue sarcomas...